Please contact us for more information or to learn if you are eligible to participate.
The purpose of the MOST study is to determine whether argatroban and/or eptifibatide is superior to placebo in improving 90-day modified Rankin scores (mRS) in acute ischemic stroke (AIS) patients treated with IV rt-PA (0.9mg/kg) or TNK (0.25mg/kg) within three hours of symptom onset.
Patricia Fernandez, M.D.
Washington University School of Medicine / National Institute of Neurological Disorders and Stroke (NINDS)
Type of Trial